Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Linker, C. A.
Right arrow Articles by Farbstein, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Linker, C. A.
Right arrow Articles by Farbstein, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Improved results of treatment of adult acute lymphoblastic leukemia

CA Linker, LJ Levitt, M O'Donnell, CA Ries, MP Link, SJ Forman and MJ Farbstein

We designed a treatment program to improve the outcome for adults with acute lymphoblastic leukemia (ALL). Treatment included a remission- induction phase followed by intensive alternating cycles of non-cross- resistant chemotherapy and prolonged oral maintenance therapy. Eighty- one consecutive previously untreated patients were entered on this study. Ninety-four percent of patients entered complete remission. A Kaplan-Meier analysis predicts that 53% +/- 9% (SEM) of patients in remission will remain free of disease at 3 years. Neither age, sex, WBC count, nor immunophenotype had a significant effect on remission duration. This program of intensive cyclical chemotherapy has improved the disease-free survival of patients with adult ALL.

Volume 69, Issue 4, pp. 1242-1248, 04/01/1987
Copyright © 1987 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Oncol Pharm PractHome page
J. A. Skirvin, A. W. Valley, V. Relias, and A. K. Morris
6-Mercaptopurine hepatotoxicity during acute lymphocytic leukemia maintenance therapy
Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 117 - 120.
[Abstract] [PDF]

Home page
 BloodHome page
K. Geissler, E. Koller, E. Hubmann, D. Niederwieser, W. Hinterberger, D. Geissler, P. Kyrle, P. Knobl, I. Pabinger, R. Thalhammer, et al.
Granulocyte Colony-Stimulating Factor as an Adjunct to Induction Chemotherapy for Adult Acute Lymphoblastic Leukemia --- A Randomized Phase-III Study
Blood, July 15, 1997; 90(2): 590 - 596.
[Abstract] [Full Text] [PDF]


click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1987 by American Society of Hematology         Online ISSN: 1528-0020